{
    "clinical_study": {
        "@rank": "72102", 
        "arm_group": {
            "arm_group_label": "Viviant treatment group", 
            "description": "Viviant treatment group"
        }, 
        "brief_summary": {
            "textblock": "This survey is conducted for preparing application material for re examination under the\n      Pharmaceutical Affairs Laws and its Enforcement Regulation, and assessing the safety and\n      efficacy profiles of VIVIANT in usual practice according to the Re-examination Regulation\n      for New Drugs"
        }, 
        "brief_title": "Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoporosis", 
        "condition_browse": {
            "mesh_term": "Osteoporosis"
        }, 
        "detailed_description": {
            "textblock": "continuous enrollment"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Postmenopausal osteoporosis and osteopenia patients\n\n        Exclusion Criteria:\n\n          -  Patients with active or past history of venous thromboembolic events including deep\n             vein thrombosis,\n\n          -  Patients with pulmonary embolism and retinal vein thrombosis"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Postmenopausal osteoporosis and osteopenia patients"
            }
        }, 
        "enrollment": {
            "#text": "3000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01793142", 
            "org_study_id": "B1781047"
        }, 
        "intervention": {
            "arm_group_label": "Viviant treatment group", 
            "description": "Viviant (Bazedoxifene) 20mg once daily", 
            "intervention_name": "Viviant", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Osteoporosis", 
            "postmenopausal", 
            "SERM"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1781047&StudyName=Post%20Marketing%20Surveillance%20For%20General%20Drug%20Use%20To%20Assess%20the%20Safety%20And%20Efficacy%20Profile%20Of%20Viviant%20In%20Usual%20Practice"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Dong-Gu", 
                        "country": "Korea, Republic of", 
                        "state": "Daejeon", 
                        "zip": "300-709"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goyang-Si", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-Do", 
                        "zip": "410-831"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jinju-Si", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeongsangnam-Do", 
                        "zip": "660-987"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of", 
                        "zip": "607-712"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyeonggi-do", 
                        "country": "Korea, Republic of", 
                        "zip": "442-022"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "158-738"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Post Marketing Surveillance For General Drug Use To Assess The Safety And Efficacy Profile Of Viviant In Usual Practice", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to [study drug] was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.", 
            "measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01793142"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "event of osteoporosis related fracture and change of surrogate marker", 
            "measure": "event of osteoporosis", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}